- Home
- GLMD vs VIVS Comparison
GLMD vs VIVS Comparison
Compare GLMD & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLMD | VIVS |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | Israel | United States |
| Employees | N/A | 9 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.9M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | GLMD | VIVS |
|---|---|---|
| Price | $0.66 | $1.82 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.5K | ★ 70.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $1.42 |
| 52 Week High | $2.67 | $5.30 |
Technical Indicators
Market Signals| Indicator | GLMD | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 43.36 |
| Support Level | $0.50 | $1.75 |
| Resistance Level | $0.69 | $2.14 |
| Average True Range (ATR) | 0.05 | 0.12 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 52.95 | 2.08 |
Price Performance
Historical ComparisonAbout GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
About VIVS VivoSim Labs Inc.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.